Trials / Completed
CompletedNCT04565990
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selexipag | Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily. |
Timeline
- Start date
- 2021-05-03
- Primary completion
- 2023-11-10
- Completion
- 2023-11-10
- First posted
- 2020-09-28
- Last updated
- 2025-05-01
- Results posted
- 2024-11-20
Locations
13 sites across 6 countries: Belarus, India, Romania, South Korea, Taiwan, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04565990. Inclusion in this directory is not an endorsement.